1447701-11-2

Upstream product

• 1447701-09-8 (1S,2R)-3-(benzyloxy)-1-((3aR,4R,6S,7aS)-6-(methoxycarbonyl)-2-oxo-6-(phenylthio)hexahydro-2H-pyrano[3,4-d]oxazol-4-yl)propane-1,2-diyl diacetate 
• 107-66-4 dibutyl phosphate 
• 1246533-87-8 C₂₄H₂₇NO₈S 

Downstream Products

• 1447701-15-6 (1S,2R)-1-((3aR,4R,6S,7aS)-6-((2S,3R,4S,5S,6R)-3-(benzoyloxy)-6-(benzyloxymethyl)-5-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-4-yloxy)-6-(methoxycarbonyl)-2-oxohexahydro-2H-pyrano[3,4-d]oxazol-4-yl)-3-(benzyloxy)propane-1,2-diyl diacetate 

Relevant academic research and scientific papers

Synthesis and vaccine evaluation of the tumor-associated carbohydrate antigen RM2 from prostate cancer

We have successfully developed a [1+2+3] one-pot strategy to synthesize the RM2 antigen hexasaccharide that was proposed to be a prostate tumor antigen. The structure of the synthetic product was verified by NMR analysis and antibody binding assay using a glycan microarray. In addition, the synthetic antigen was conjugated to a mutated diphtheria toxin (DT, CRM197) with different copy numbers and adjuvant combinations to form the vaccine candidates. After vaccination in mice, we used glycan microarrays to monitor their immune response, and the results indicated that, when one molecule of DT was incorporated with 4.7 molecules of RM2 on average (DT-RM4.7) and adjuvanted with the glycolipid C34, the combination exhibited the strongest anti-RM2 IgG titer. Moreover, the induced mouse antibodies mediated effective complement-dependent cytotoxicity (CDC) against the prostate cancer cell line LNCap.